Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Ph.D. Student: Karina Hedelund Gravgaard Enrolment: 1 July 2010 Project Title: MicroRNAs associated with tumor progression and endocrine resistance in breast cancer tumors Supervisors: Professor Henrik J. Ditzel, dr.med, PhD,Consultant Anne-Vibeke Lænkholm Consultant Ann Knoop Institute: Institute of Molecular Medicine Research Unit: Cancer and Inflammation Research Abstract: Introduction: Approximately 80% of diagnosed breast cancers are estrogen receptor-positive (ER+) and receive adjuvant endocrine treatment with either Tamoxifen or aromatase inhibitors (AI), thereby reducing the overall risk of development of metastases. However, approximately 30% of the ER+ breast cancer patients still develop metastases indicating that detection of ER by itself is not sufficient to predict benefit of endocrine therapy. Therefore the identification of additional predictive biomarkers is crucial for optimization of the efficacy of current treatments of ER+ breast cancers. The purpose of this translational project is to identify and validate microRNA (miRNA) markers that potentially can be used to assist clinicians in choice of optimal treatment of breast cancer. These studies will focus on identification of miRNAs 1) specifically associated with endocrine treatment response in patients with ER+ breast cancer and 2) predictive of progression of DCIS. The miRNAs will be identified by comparing the global miRNA expression profile of a large number of tumor samples from patients with vs. without recurrence following long-term endocrine treatment and by comparing the global miRNA expression of tissue from DCIS cases that resulted in local recurrence with those that did not. An additional purpose of the project is to study miRNA expression alterations associated with metastasis as we have recently identified miRNAs that may be central in the metastatic process. Our study thus addresses three clinical very important areas and should in long term bring insight to the biology of miRNAs and improve the treatment of breast cancer patients. Methods: Global miRNA analysis: microarray or a qPCR platform. Validation: miRNA qRT-PCR. Validated miRNAs will be investigated using endocrine resistant cell lines where the miRNAs will be either knocked down or over expressed in the cell lines for functional studies. Protein expression of potential miRNA targets in breast cancers tissue and corresponding metastases will be investigated using immunohistochemical (IHC) analysis and the cellular localization of the differentially expressed miRNAs will be investigated using in situ hybridization. Current status: The IHC analysis has been performed and in situ hybridization of two of the identified miRNAs is being performed at the moment. Keywords: Oncology and Haematology